AMANDA MAVOR: Open Payments
NPI 1396442307 · SARASOTA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,606 in 91 payments from 35 companies in 2025. Trend: 2023 $1,184 · 2024 $3,228 · 2025 $2,606
Food & beverage: $2,152Education: $454
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $389 |
| Merck Sharp & Dohme LLC | 9 | $220 |
| Ipsen Biopharmaceuticals, Inc | 3 | $198 |
| Daiichi Sankyo Inc. | 6 | $176 |
| Novartis Pharmaceuticals Corporation | 8 | $144 |
| AstraZeneca Pharmaceuticals LP | 7 | $141 |
| E.R. Squibb & Sons, L.L.C. | 5 | $124 |
| Gilead Sciences, Inc. | 5 | $119 |
| GlaxoSmithKline, LLC. | 4 | $105 |
| Janssen Biotech, Inc. | 2 | $104 |
Products named: VENCLEXTA, KEYTRUDA, Enhertu, OPDIVO, Trodelvy, BRUKINSA, LIBTAYO, ERLEADA.
Industry payments across FL — which companies pay providers there.
